Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study
We investigated serum total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain after BNT162b2 mRNA vaccination against coronavirus disease 2019 (COVID-19) in Japanese patients taking various immunosuppressive medications for rheumatic disease. In 212 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers (controls), all of whom had received 2 doses of BNT162b2 vaccine, serum antibody titers of SARS-CoV-2 spike protein were analyzed at least 14 days after the second dose. Many of the patients were taking immunosuppre...
Source: Medicine - October 21, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
We examined differences in antibody levels depending on the vaccine and treatment at baseline while adjusting for age, disease, and past SARS-CoV-2 infection. 565 IRD patients provided eligible samples. Among monotherapies, rituximab, abatacept, JAKi, and TNFi had the highest odds of reduced anti-S1 responses compared to no medication. Patients on specific combination therapies showed significantly lower antibody responses than those on monotherapy. Irrespective of the disease, treatment, and past SARS-CoV-2 infection, the odds of higher antibody levels at 4, 12, and 24 weeks post second vaccine dose were, respectively, 3....
Source: Frontiers in Immunology - October 13, 2022 Category: Allergy & Immunology Source Type: research
Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
We read with great interest the article by Pappas et al1 who evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) such as adalimumab, etanercept, certolizumab pegol, golimumab or infliximab versus a non-TNFi (abatacept, tocilizumab, rituximab, anakinra or tofacitinib) as the first-line treatment in patients with rheumatoid arthritis (RA). The authors concluded that there were no statistically significant differences observed between the TNFi and non-TNFi treatment groups for the outcomes assessed, including the Clinical Disease Activity Index (CDAI), the 28-Joint Modified Disease Activity Sc...
Source: Annals of the Rheumatic Diseases - October 12, 2022 Category: Rheumatology Authors: Zheng, W., Leong, P.-Y., Wei, J. C.-C. Tags: ARD Correspondence Source Type: research
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study
Conclusions
The two-dose BNTb262 regimen was associated with similar clinical efficacy and similar waning of the humoral response over 6 months among patients with AIIRD and controls. The third vaccine dose restored the humoral response in all of the controls and the majority of patients. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - October 12, 2022 Category: Rheumatology Authors: Furer, V., Eviatar, T., Freund, T., Peleg, H., Paran, D., Levartovsky, D., Kaufman, I., Broyde, A., Elalouf, O., Polachek, A., Feld, J., Haddad, A., Gazitt, T., Elias, M., Higazi, N., Kharouf, F., Gertel, S., Pel, S., Nevo, S., Hagin, D., Zisman, D., Elka Tags: ARD Lay summaries, ARD, Epidemiology Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: J Rheumatol)
Source: J Rheumatol - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: J Rheumatol)
Source: J Rheumatol - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: J Rheumatol)
Source: J Rheumatol - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: J Rheumatol)
Source: J Rheumatol - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: J Rheumatol)
Source: J Rheumatol - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
CONCLUSION: In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.PMID:36182107 | DOI:10.3899/jrheum.220469 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - October 1, 2022 Category: Rheumatology Authors: Carolina A Isnardi Osvaldo L Cerda Margarita Landi Leonel Cruces Emilce E Schneeberger Claudia Calle Montoro Mar ía Agustina Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto Alejandro Ezquer Mar ía G Crespo Rocha Camila R Reyes G óm Source Type: research
